The purpose of this study is to examine the effect CGM (continuous glucose monitoring) has on subjects with type 2 diabetes. It is anticipated that patients using the device will obtain tighter control of their blood sugars resulting in measureable health benefits and improved confidence in their ability to manage their diabetes.
Full Title of Study: “Continuous Glucose Monitoring in Subjects With Type 2 Diabetes”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 2011
Arms, Groups and Cohorts
- Basal insulin, approved oral medications
Clinical Trial Outcome Measures
- Change in HgbA1c
- Time Frame: Measured at 6 months
- Percentage of Time Spent at Glycemic Levels <65 mg/dl
- Time Frame: Measured at baseline and at 6 months
- Change in Percentage of Time Spent at Glycemic Levels >180 mg/dl
- Time Frame: Measured at baseline and 6 months
- Change in Basal Insulin Dose From Baseline Values
- Time Frame: Assessed at baseline and 6 months
Participating in This Clinical Trial
- Have been diagnosed with type 2 diabetes mellitus
- Have an HgbA1c value ≥ 7% and ≤17%.
- Are on basal insulin, with or without oral agents
- Are not on basal bolus insulin therapy.
- Have had no severe hypoglycemic episodes in the 6 months prior to enrollment in the study. Severe hypoglycemia will be defined as any hypoglycemia that is both neurologically impairing and absolutely requires assistance from a third party in the form of carbohydrates, glucagon shots, or attention from a paramedic or other healthcare professional.
- Have no known allergy to medical tape or sensors.
- Are capable of and willing to test their blood glucose (BG) on an average of 4 times per day.
- Are willing to not use Acetaminophen while enrolled in the study.
- Are willing not to undergo a MRI procedure while wearing the CGM sensor.
- Are willing and capable of performing self insertions of the device sensor.
- Women of child bearing potential must be willing to use an approved form of birth control while enrolled in the study.
- Women of child bearing potential must be willing to perform pregnancy tests monthly while enrolled in the study.
- Can understand and speak English fluently.
- Have been on pump therapy in the 6 months prior to enrollment in the study.
- Are receiving basal- bolus insulin therapy
- Are taking any medication that is not approved to be taken with insulin.
- Are pregnant or have intentions of becoming pregnant during the duration of the study.
- Have any skin condition that would inhibit the proper wearing of the CGM sensor including severe psoriasis, burns, eczema, scarring, excessive tattoos, etc.
- Have a hematocrit ≤30% or ≥55%
- Are currently enrolled in another clinical study (subjects must have ended participation in other studies at least 30 days prior to enrolling in this study.
- Are employed by any company that manufactures or is developing a CGM device.
- Are deemed incapable of participating in the study by the Primary Investigator for any reason.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Rocky Mountain Diabetes and Osteoporosis Center
- Provider of Information About this Clinical Study
- Principal Investigator: David Liljenquist, M.D., Primary Investigator – Rocky Mountain Diabetes and Osteoporosis Center
- Overall Official(s)
- David R. Liljenquist, MD, Principal Investigator, Rocky Mountain Diabetes and Osteoporosis Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.